CAS
ZYME icon

Coppell Advisory Solutions’s Zymeworks ZYME Stock Holding History

Coppell Advisory Solutions’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,661
Closed -$48.3K – 1586
2023
Q2 		$48.3K Buy
+5,661
New +$50.7K 0.01% 377

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Coppell Advisory Solutions's ZYME Position: Q3 2023 in Review

Coppell Advisory Solutions sold out of Zymeworks (ZYME) in Q3 2023, closing a stake of 5,661 shares — an estimated $48.3K sold.

Coppell Advisory Solutions first reported a position in ZYME in Q2 2023 and held it in 1 quarter. The position peaked at $48.3K in Q2 2023. 139 funds tracked by Wall St. Rank hold ZYME as of Q3 2023.

  • Coppell Advisory Solutions reported no remaining Zymeworks position as of Q3 2023 after selling out during the quarter.
  • Coppell Advisory Solutions sold 5,661 Zymeworks shares in Q3 2023, an estimated $48.3K.
  • Coppell Advisory Solutions first reported a position in Zymeworks in Q2 2023 and held it in 1 quarter.
  • Coppell Advisory Solutions's Zymeworks position peaked at $48.3K in Q2 2023.
  • 139 funds tracked by Wall St. Rank held Zymeworks as of Q3 2023.

Based on Coppell Advisory Solutions's 13F filing for Q3 2023, filed 14 Nov 2023.